Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results, Misses Estimates By $0.09 EPS

Zenas BioPharma (NASDAQ:ZBIO) issued its quarterly earnings data on Wednesday. The company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.09), FiscalAI reports. During the same period in the previous year, the company posted ($0.80) earnings per share.

Zenas BioPharma Stock Up 4.0%

Shares of Zenas BioPharma stock traded up $0.77 during midday trading on Wednesday, reaching $19.93. 516,448 shares of the company’s stock traded hands, compared to its average volume of 863,871. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -2.55 and a beta of -0.61. The company’s 50 day simple moving average is $21.59 and its 200 day simple moving average is $26.88. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. Zenas BioPharma has a 52 week low of $8.53 and a 52 week high of $44.60.

Analysts Set New Price Targets

ZBIO has been the subject of several recent analyst reports. Zacks Research cut shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. Morgan Stanley increased their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday, March 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Guggenheim raised their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Finally, Citigroup dropped their price target on Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Zenas BioPharma currently has a consensus rating of “Hold” and a consensus target price of $44.14.

Insider Buying and Selling at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. bought 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The shares were purchased at an average price of $17.62 per share, for a total transaction of $616,700.00. Following the acquisition, the chief executive officer directly owned 1,786,039 shares of the company’s stock, valued at $31,470,007.18. The trade was a 2.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Patricia L. Allen bought 15,700 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $24.85 per share, for a total transaction of $390,145.00. Following the acquisition, the director directly owned 15,700 shares in the company, valued at approximately $390,145. This trade represents a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 233,628 shares of company stock worth $4,637,200 over the last quarter. Company insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ZBIO. Geode Capital Management LLC grew its position in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after purchasing an additional 8,207 shares during the period. Sei Investments Co. bought a new position in shares of Zenas BioPharma during the 2nd quarter worth approximately $118,000. Bank of America Corp DE lifted its position in shares of Zenas BioPharma by 32.3% during the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after buying an additional 3,412 shares during the period. Finally, Vanguard Group Inc. boosted its position in Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after buying an additional 170,546 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.